Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China
IntroductionIn October 2017, China initiated adjustments to the registration procedures for imported drugs to promote accessibility to overseas drugs. In support of this decision, the National Medical Products Administration (NMPA) issued a technical guideline regarding accepting foreign clinical tr...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-07-01
|
| Col·lecció: | Frontiers in Public Health |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1512148/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|